The C-Reactive Protein-to-Albumin Ratio in Chronic Lymphocytic Leukemia: Links to Disease Biology, Treatment Response, and Survival

Authors

  • Shimaa Abdelmoneem, Ayman Fathy Arafa, Noura Mostafa Kamel Mohamed, Mohammed Gamal Mohammed Alshamy Author

DOI:

https://doi.org/10.48047/ge7efw20

Keywords:

Chronic lymphocytic leukemia; C-reactive protein-to-albumin ratio; systemic inflammation; prognostic biomarker; treatment response; survival.

Abstract

Background: Chronic lymphocytic leukemia (CLL) is characterized by marked clinical heterogeneity, ranging from indolent disease requiring prolonged observation to rapidly progressive leukemia associated with treatment resistance and shortened survival. Established prognostic models incorporate clinical stage, molecular abnormalities, immunoglobulin heavy-chain variable-region gene status, serum β2microglobulin, and selected cytogenetic lesions. Nevertheless, several of these assessments are costly

Downloads

Download data is not yet available.

References

Hallek M. Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy. Am J Hematol. 2025;100(3):450-480.

Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918-932

Downloads

Published

2024-11-20

How to Cite

The C-Reactive Protein-to-Albumin Ratio in Chronic Lymphocytic Leukemia: Links to Disease Biology, Treatment Response, and Survival (Shimaa Abdelmoneem, Ayman Fathy Arafa, Noura Mostafa Kamel Mohamed, Mohammed Gamal Mohammed Alshamy , Trans.). (2024). Cuestiones De Fisioterapia, 53(03), 8624-8630. https://doi.org/10.48047/ge7efw20